FDA Blocks Medical Innovation

Balaji Srinivasan shares his perspective on the FDA as a barrier to medical innovation, drawing parallels to how alternative systems can create change. He emphasizes that reform comes not through internal change, but through building parallel systems.

Key Points:

• FDA as Innovation Blocker:

  • Acts as primary blocker of medical innovation globally
  • Risk aversion is not optimal for progress
  • Creates both Type 1 and Type 2 errors in approvals

• Problems with FDA Decision Making:

  • Focuses too heavily on PR downside of approving bad products
  • Ignores the "unseen" damage of not approving good products
  • Example: Held back COVID testing and J&J vaccine over minimal risks (1 in 1M blood clots)

• Reform Strategy:

  • Cannot simply abolish FDA, similar to how can't abolish Federal Reserve
  • Change comes through building parallel systems, not internal reform
  • Similar to how Google didn't reform Microsoft directly, but built alternative system

• Building Parallel Systems:

  • Must be ethical and opt-in for all participants
  • Allow people to choose their level of risk tolerance
  • Similar to cryptocurrency's approach to traditional finance:
    • Completely voluntary participation
    • Users accept all risks and technical difficulties
    • Ability to fork and create alternatives if disagreement exists

• Future Vision:

  • Need parallel systems for medical innovation
  • Similar to how crypto created alternative to traditional finance
  • Focus on building outside existing system rather than trying to change from within